Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Potent universal beta-coronavirus therapeutic activity mediated by direct respiratory administration of a Spike S2 domain-specific human neutralizing monoclonal antibody
Michael S. Piepenbrink, Jun‐Gyu Park, Ashlesha Deshpande, et al.
PLoS Pathogens (2022) Vol. 18, Iss. 7, pp. e1010691-e1010691
Open Access | Times Cited: 27

Showing 1-25 of 27 citing articles:

Monoclonal antibody therapies against SARS-CoV-2
Daniele Focosi, Scott A. McConnell, Arturo Casadevall, et al.
The Lancet Infectious Diseases (2022) Vol. 22, Iss. 11, pp. e311-e326
Open Access | Times Cited: 214
Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease
Pan-Pan Zhou, Ge Song, Hejun Liu, et al.
Immunity (2023) Vol. 56, Iss. 3, pp. 669-686.e7
Open Access | Times Cited: 118
Identification of a conserved S2 epitope present on spike proteins from all highly pathogenic coronaviruses
Rui P. Silva, Yimin Huang, Annalee W. Nguyen, et al.
eLife (2023) Vol. 12
Open Access | Times Cited: 66
Protective neutralizing epitopes in SARS‐CoV‐2
Hejun Liu, Ian A. Wilson
Immunological Reviews (2022) Vol. 310, Iss. 1, pp. 76-92
Open Access | Times Cited: 40
SARS-CoV-2 spike S2-specific neutralizing antibodies
Chia‐Jung Li, Shih‐Chung Chang
Emerging Microbes & Infections (2023) Vol. 12, Iss. 2
Open Access | Times Cited: 35
Treatments for COVID-19
Hayden S. Andrews, Jonathan D. Herman, Rajesh T. Gandhi
Annual Review of Medicine (2023) Vol. 75, Iss. 1, pp. 145-157
Closed Access | Times Cited: 28
Comprehensive Overview of Broadly Neutralizing Antibodies against SARS-COV-2 Variants
Lingyan Cui, Tingting Li, Wenhui Xue, et al.
(2024)
Open Access | Times Cited: 6
Overcoming antibody-resistant SARS-CoV-2 variants with bispecific antibodies constructed using non-neutralizing antibodies
Tetsuya Inoue, Yuichiro Yamamoto, Kaoru Sato, et al.
iScience (2024) Vol. 27, Iss. 4, pp. 109363-109363
Open Access | Times Cited: 5
Current Status and Perspectives of Therapeutic Antibodies Targeting the Spike Protein S2 Subunit against SARS-CoV-2
Yuichiro Yamamoto, Tetsuya Inoue
Biological and Pharmaceutical Bulletin (2024) Vol. 47, Iss. 5, pp. 917-923
Open Access | Times Cited: 5
Comprehensive Overview of Broadly Neutralizing Antibodies against SARS-CoV-2 Variants
Lingyan Cui, Tingting Li, Wenhui Xue, et al.
Viruses (2024) Vol. 16, Iss. 6, pp. 900-900
Open Access | Times Cited: 5
Immunity to Seasonal Coronavirus Spike Proteins Does Not Protect from SARS-CoV-2 Challenge in a Mouse Model but Has No Detrimental Effect on Protection Mediated by COVID-19 mRNA Vaccination
Fatima Amanat, Jordan J. Clark, Juan Manuel Carreño, et al.
Journal of Virology (2023) Vol. 97, Iss. 3
Open Access | Times Cited: 12
Aerosol delivery of SARS-CoV-2 human monoclonal antibodies in macaques limits viral replication and lung pathology
Daniel N. Streblow, Alec J. Hirsch, Jeffrey J. Stanton, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 12
A human monoclonal antibody neutralizing SARS-CoV-2 Omicron variants containing the L452R mutation
Saskia C. Stein, Guido Hansen, George Ssebyatika, et al.
Journal of Virology (2024)
Open Access | Times Cited: 4
A Structural Voyage Toward the Landscape of Humoral and Cellular Immune Escapes of SARS‐CoV‐2
Jun Liu, Yan Wu, George F. Gao
Immunological Reviews (2025) Vol. 330, Iss. 1
Closed Access
Unveiling the Complete Spectrum of SARS-CoV-2 Fusion Stages by In Situ Cryo-ET
Caner Akıl, Jialu Xu, Juan Shen, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Monoclonal Antibodies for Pediatric Viral Disease Prevention and Treatment
Zeynep BAHADIR, Priyanka Narayan, Rachael M. Wolters, et al.
PEDIATRICS (2025)
Closed Access
Respiratory delivery of passive immunotherapies for SARS-CoV-2 prophylaxis and therapy
Daniele Focosi, Fabrizio Maggi
Human Vaccines & Immunotherapeutics (2023) Vol. 19, Iss. 2
Open Access | Times Cited: 7
Broad sarbecovirus neutralization by combined memory B cell antibodies to ancestral SARS-CoV-2
Cyril Planchais, I. Fernández, Benjamin Chalopin, et al.
iScience (2024) Vol. 27, Iss. 7, pp. 110354-110354
Open Access | Times Cited: 2
Acquisition of Furin Cleavage Site and Further SARS-CoV-2 Evolution Change the Mechanisms of Viral Entry, Infection Spread, and Cell Signaling
Elena I. Frolova, Oksana Palchevska, Tetyana Lukash, et al.
Journal of Virology (2022) Vol. 96, Iss. 15
Open Access | Times Cited: 11
Status and Developing Strategies for Neutralizing Monoclonal Antibody Therapy in the Omicron Era of COVID-19
Zuning Ren, Chenguang Shen, Jie Peng
Viruses (2023) Vol. 15, Iss. 6, pp. 1297-1297
Open Access | Times Cited: 6
Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that bind a conserved membrane proximal epitope of the spike
Sieglinde De, Inge Van Molle, Loes van Schie, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 4
Structure and epitope of a neutralizing monoclonal antibody that targets the stem helix of β coronaviruses
Ashlesha Deshpande, Nobert Schormann, Mike S. Piepenbrink, et al.
FEBS Journal (2023) Vol. 290, Iss. 13, pp. 3422-3435
Open Access | Times Cited: 4
Design of the conserved epitope peptide of SARS-CoV-2 spike protein as the broad-spectrum COVID-19 vaccine
Ting‐Yu Chang, Chia‐Jung Li, Tai‐Ling Chao, et al.
Applied Microbiology and Biotechnology (2024) Vol. 108, Iss. 1
Open Access | Times Cited: 1
Fc-Effector-Independent in vivo Activity of a Potent Influenza B Neuraminidase Broadly Neutralizing Antibody
Ahmed Magdy Khalil, Michael S. Piepenbrink, Ian Markham, et al.
Viruses (2023) Vol. 15, Iss. 7, pp. 1540-1540
Open Access | Times Cited: 2
Overcoming antibody-resistant SARS-CoV-2 variants with bispecific antibodies constructed using non-neutralizing antibodies
Tetsuya Inoue, Yuichiro Yamamoto, Kaoru Sato, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top